1. Home
  2. IRD vs FSEA Comparison

IRD vs FSEA Comparison

Compare IRD & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • FSEA
  • Stock Information
  • Founded
  • IRD 2018
  • FSEA 1890
  • Country
  • IRD United States
  • FSEA United States
  • Employees
  • IRD N/A
  • FSEA N/A
  • Industry
  • IRD
  • FSEA Savings Institutions
  • Sector
  • IRD
  • FSEA Finance
  • Exchange
  • IRD NYSE
  • FSEA Nasdaq
  • Market Cap
  • IRD 62.0M
  • FSEA 53.3M
  • IPO Year
  • IRD N/A
  • FSEA N/A
  • Fundamental
  • Price
  • IRD $0.95
  • FSEA $11.31
  • Analyst Decision
  • IRD Strong Buy
  • FSEA
  • Analyst Count
  • IRD 3
  • FSEA 0
  • Target Price
  • IRD $6.33
  • FSEA N/A
  • AVG Volume (30 Days)
  • IRD 2.4M
  • FSEA 6.0K
  • Earning Date
  • IRD 08-15-2025
  • FSEA 08-08-2025
  • Dividend Yield
  • IRD N/A
  • FSEA N/A
  • EPS Growth
  • IRD N/A
  • FSEA N/A
  • EPS
  • IRD N/A
  • FSEA 0.00
  • Revenue
  • IRD $13,651,000.00
  • FSEA $16,196,000.00
  • Revenue This Year
  • IRD $51.41
  • FSEA N/A
  • Revenue Next Year
  • IRD $68.84
  • FSEA N/A
  • P/E Ratio
  • IRD N/A
  • FSEA $1,381.37
  • Revenue Growth
  • IRD N/A
  • FSEA 97.61
  • 52 Week Low
  • IRD $0.65
  • FSEA $8.60
  • 52 Week High
  • IRD $2.18
  • FSEA $11.80
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • FSEA 51.70
  • Support Level
  • IRD N/A
  • FSEA $11.00
  • Resistance Level
  • IRD N/A
  • FSEA $11.33
  • Average True Range (ATR)
  • IRD 0.00
  • FSEA 0.17
  • MACD
  • IRD 0.00
  • FSEA -0.01
  • Stochastic Oscillator
  • IRD 0.00
  • FSEA 60.00

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About FSEA First Seacoast Bancorp Inc.

First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.

Share on Social Networks: